5 Reasons Why “It’s Not Going to be ICER”

5 Reasons Why “It’s Not Going to be ICER”

Most patients have never heard of the Institute for Clinical and Economic Review, but it plays a central role in deciding our access to the treatments prescribed by our doctors. That’s because ICER works with insurance companies to evaluate how medical treatments...
ICER jeopardizes access to new sickle cell treatments

ICER jeopardizes access to new sickle cell treatments

Patients living with sickle cell disease could run into more insurance barriers as a result of a pending report on two potentially groundbreaking SCD treatments. The Institute for Clinical and Economic Review, which receives support from insurance companies, has begun...
Could ICER block research into cure for Alzheimer’s?

Could ICER block research into cure for Alzheimer’s?

Alzheimer’s disease exacts a devastating toll on patients and caregivers. “Many people end up in long-term care or nursing homes, and require around-the-clock care for many years,”explains Keith Fargo, director of scientific programs and outreach for the...
H1088: Mass. lawmakers propose ban on anti-patient QALY formula

H1088: Mass. lawmakers propose ban on anti-patient QALY formula

A controversial healthcare formula that is frequently used to deny patients care and boost insurance profits could soon be banned in Massachusetts. Three Massachusetts state representatives, Angelo J. Puppolo, Jr., José F. Tosado and Bud L. Williams, have introduced...
Cardio patients need access to additive therapies

Cardio patients need access to additive therapies

They’re considered the first line treatment choice for millions of patients living with cardiovascular disease and high cholesterol. But, for many patients living with cardiovascular disease, statins alone don’t work. “My legs were hurting. I thought I was getting the...